Palatin Technologies, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2014. The filing also reports the quarter ended June 30, 2014; it is not a standalone quarterly filing. The 10-K was filed September 12, 2014.
Business context
Palatin is a development-stage biopharmaceutical company with no approved products or meaningful recurring revenue. Its lead program is bremelanotide, an on-demand injectable in development for female sexual dysfunction (FSD). Other programs include PL-3994 for cardiovascular and pulmonary conditions and early-stage melanocortin receptor candidates. The company relies on collaborations, existing cash and external financing to fund development.
Financial results and liquidity
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Revenue | $0 | $10,361 |
| Research and development expense | $10.8 million | $10.5 million |
| General and administrative expense | $5.0 million | $5.1 million |
| Operating loss | $15.8 million | $15.6 million |
| Net loss | $13.9 million | $20.9 million |
| Net loss per share | $0.13 | $0.21 |
| Cash used in operating activities | $12.2 million | $13.6 million |
FY 2014 revenue was zero; FY 2013 revenue was largely collaboration-related reimbursement. The lower net loss in FY 2014 primarily reflects the absence of FY 2013’s $7.0 million non-cash warrant fair-value charge, rather than a material improvement in operating performance. FY 2014 included a $1.85 million tax benefit from selling New Jersey net operating loss carryforwards.
At June 30, 2014, cash and cash equivalents were $12.2 million, current assets were $12.3 million and current liabilities were $2.8 million, including $1.0 million of unearned revenue. The filing reports no off-balance-sheet arrangements; the remaining capital lease was paid in FY 2014. It lists $236,335 of remaining operating lease payments. In September 2014, Palatin received $8.8 million from Gedeon Richter. Management said available resources, including that payment, were expected to fund planned operations through September 30, 2015, excluding initiation of pivotal Phase 3 and other planned clinical trials.
In the quarter ended June 30, 2014, revenue was zero and net loss was $4.32 million, or $0.04 per share.
Material changes and development updates
- FY 2014 operating cash use declined from $13.6 million to $12.2 million, while R&D expense increased modestly from $10.5 million to $10.8 million.
- Palatin reported positive Phase 2B bremelanotide results, including a statistically significant increase in satisfying sexual events at the 1.75 mg dose versus placebo. Common adverse events included flushing, nausea and vomiting; fewer than 3% discontinued due to adverse events, and no serious adverse event was attributed to the drug.
- In August 2014, Palatin signed a European and selected-country license, co-development and commercialization agreement with Gedeon Richter. Palatin reported total upfront payments of €7.5 million (about $9.8 million), including the $8.8 million received in September. A further €2.5 million milestone is due upon initiation of the U.S. Phase 3 program; the agreement also provides for potential regulatory and sales milestones of up to €80 million and low double-digit royalties. Palatin will share European co-development costs; Gedeon Richter will lead commercial activities in its territory.
- AstraZeneca discontinued development of AZD2820 after a serious adverse event in a Phase 1 trial. Palatin said a connection to the drug could not be excluded; AstraZeneca was evaluating next steps for its broader program.
Outlook, risks and contingencies
Palatin planned to begin bremelanotide Phase 3 enrollment in the fourth quarter of calendar 2014, subject to having adequate funding or commitments to complete the program. The company estimated Phase 3 and related regulatory filings would cost at least $80 million and expected the program to take at least 18 months from first patient dosing through database lock. Additional financing or partnering is therefore central to the plan; management warned that trials could be curtailed or delayed if funds are insufficient.
Other planned work included seeking to file an IND for PL-8177 as early as the fourth quarter of calendar 2014 and, subject to funding, beginning Phase 1 in the first half of 2015. A repeat-dose Phase 2 trial of PL-3994 was also planned for the first half of 2015, contingent on funds. These are plans, not assured milestones.
Key risks include continued losses, uncertain clinical outcomes and regulatory approval, dependence on external financing and partners, manufacturing and supply constraints, competitive products, and uncertain reimbursement and market demand for FSD treatment. The filing disclosed substantial potential dilution: as of September 11, 2014, 91.3 million shares were issuable upon exercise of warrants, including 67.5 million warrants exercisable at $0.01 per share. The 2012 private-placement investors also have financing participation rights and specified change-of-control protections. Palatin reported no pending legal matter expected to have a material adverse effect. Its financial statements received an unqualified audit opinion.
Important facts for investors to verify
- Whether Palatin obtained sufficient financing or a partner commitment to fund the full bremelanotide Phase 3 program, and whether enrollment began on schedule.
- The definitive Gedeon Richter agreement’s milestone conditions, cost-sharing obligations, termination provisions and subsequent payments.
- Updated cash runway and burn rate, particularly whether the stated runway excludes the Phase 3 program and other trials as described.
- Warrant and other potentially dilutive share counts, exercise terms, registration status and the effects of the private-placement financing rights.
- Subsequent clinical and regulatory developments for bremelanotide, PL-3994, PL-8177 and AstraZeneca’s licensed program.